Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
December 19, 2024 08:30 ET
|
Tevogen Bio Inc
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
December 18, 2024 07:30 ET
|
Photys Therapeutics, Incl
Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.
Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
December 18, 2024 03:00 ET
|
Vandria
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today...
BHIANT Celebrates Milestones in Workforce Development and Industry Collaboration, Sets Vision for 2025
December 17, 2024 10:00 ET
|
BHIANT
DALLAS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) proudly announces significant progress in workforce development and industry...
YPrime Commits to United Nations Global Compact, Pledging to Align its Sustainable Business Practices with UN Goals
December 17, 2024 09:57 ET
|
Y-Prime, LLC
YPrime pledges to United Nations Global Compact, expanding its program of sustainable business practices.
Upstream Bio Appoints Allison Ambrose as General Counsel
December 17, 2024 08:00 ET
|
Upstream Bio
Upstream appoints Allison Ambrose as General Counsel
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
December 17, 2024 06:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
December 17, 2024 06:00 ET
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
December 16, 2024 16:30 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI...